Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of SKB103 injection in advanced solid tumors
CTR20261135Phase 2Active
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SKB103 in Nonhematologic neoplasms, sponsored by Sichuan Kelun-Biotech Biopharmaceutical. Started Apr 2026; status: active.
02
Drugs
SKB103
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20261135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261135.